The 2026 ESC heart failure guidelines: advancing science while facilitating clinical implementation

The 2026 European Society of Cardiology (ESC) guidelines for the management of heart failure introduce a series of important changes intended to simplify classification, accelerate implementation of effective therapies, and shift care toward earlier prevention and intervention. Among the most notable changes are the incorporation of patients with mildly reduced left ventricular ejection fraction into the heart failure with reduced ejection fraction category, the replacement of the traditional concept of guideline-directed medical therapy with a three-tiered framework of foundational medical therapy, additional medical therapy, and guideline-directed interventional therapy, and greater emphasis on prevention through the formal use of stages A to D. The guidelines also favor the term “decompensated heart failure” over “acute heart failure,” reinforcing the concept that clinical deterioration often reflects an evolving process rather than an abrupt event. These changes provide a clearer and more actionable clinical pathway and emphasize rapid initiation of foundational therapies and timely referral for advanced heart failure care. At the same time, simplification may reduce phenotypic granularity, and some recommendations warrant continued discussion regarding the relationship between recommendation strength and supporting evidence. The Class I recommendation for mineralocorticoid receptor antagonists in symptomatic heart failure with preserved ejection fraction illustrates this tension, particularly given differences between steroidal and non-steroidal agents and across patient phenotypes. Overall, the 2026 ESC guidelines provide a pragmatic, forward-looking framework that may improve implementation and continuity of heart failure care. Their greatest impact, however, will depend not only on scientific rigor, but also on thoughtful interpretation, individualized application, and timely translation into everyday clinical practice.

Authors

Institutions

Publication Details

Journal
Cardiology Plus
Published
2026-09-25
DOI
https://doi.org/10.1097/cp9.0000000000000177
Primary Topic
Heart Failure Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

The 2026 ESC heart failure guidelines: advancing science while facilitating clinical implementation

Gianluigi Savarese, Michael Fu, Karl Swedberg
Cardiology Plus
Heart Failure Treatment and Management
article

The 2026 ESC heart failure guidelines: advancing science while facilitating clinical implementation

Gianluigi Savarese, Michael Fu, Karl Swedberg
article en

Abstract

The 2026 European Society of Cardiology (ESC) guidelines for the management of heart failure introduce a series of important changes intended to simplify classification, accelerate implementation of effective therapies, and shift care toward earlier prevention and intervention. Among the most notable changes are the incorporation of patients with mildly reduced left ventricular ejection fraction into the heart failure with reduced ejection fraction category, the replacement of the traditional concept of guideline-directed medical therapy with a three-tiered framework of foundational medical therapy, additional medical therapy, and guideline-directed interventional therapy, and greater emphasis on prevention through the formal use of stages A to D. The guidelines also favor the term “decompensated heart failure” over “acute heart failure,” reinforcing the concept that clinical deterioration often reflects an evolving process rather than an abrupt event. These changes provide a clearer and more actionable clinical pathway and emphasize rapid initiation of foundational therapies and timely referral for advanced heart failure care. At the same time, simplification may reduce phenotypic granularity, and some recommendations warrant continued discussion regarding the relationship between recommendation strength and supporting evidence. The Class I recommendation for mineralocorticoid receptor antagonists in symptomatic heart failure with preserved ejection fraction illustrates this tension, particularly given differences between steroidal and non-steroidal agents and across patient phenotypes. Overall, the 2026 ESC guidelines provide a pragmatic, forward-looking framework that may improve implementation and continuity of heart failure care. Their greatest impact, however, will depend not only on scientific rigor, but also on thoughtful interpretation, individualized application, and timely translation into everyday clinical practice.

Cardiology Plus
Karolinska Institutet (SE), University of Gothenburg (SE)
Good health and well-being
Openalex Percentile: Top 11%
Heart Failure Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.